ANI Pharmaceuticals

ANIP

Market cap $1.78B

PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI's Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol®.

ANI Pharmaceuticals continues shifting toward rare diseases, with management projecting that this segment will represent 60% of its 2026 revenues. However, their generics remain a reliable cash engine. These products grew 28% in 2025 and reached $384 million in revenues. This way, ANIP has been able to fund its expansion into rare diseases, with Cortrophin as its flagship asset in this category.

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI's Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket®.

INTU, ANIP and GLPI stand out this April as earnings acceleration signals potential stock gains before broader market recognition kicks in.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a corticosteroid indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

ANI Pharmaceuticals recently offered up solid FY26 guidance with 15% non-GAAP EPS growth and strong momentum from Cortrophin Gel. ANIP's increasing reliance on Cortrophin Gel, projected to reach 52% of FY26 revenue, is offset by patent protection and a complex formulation. The company's balance sheet remains solid, supporting ongoing investments in rare disease expansion and 10–15 annual generic launches.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The mean of analysts' price targets for ANI (ANIP) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.